MX2012002829A - Producción de una respuesta inmune para disminuir el riesgo de contagio por brucelosis. - Google Patents

Producción de una respuesta inmune para disminuir el riesgo de contagio por brucelosis.

Info

Publication number
MX2012002829A
MX2012002829A MX2012002829A MX2012002829A MX2012002829A MX 2012002829 A MX2012002829 A MX 2012002829A MX 2012002829 A MX2012002829 A MX 2012002829A MX 2012002829 A MX2012002829 A MX 2012002829A MX 2012002829 A MX2012002829 A MX 2012002829A
Authority
MX
Mexico
Prior art keywords
risk
producing
reducing
immune response
brucellosis
Prior art date
Application number
MX2012002829A
Other languages
English (en)
Inventor
Gerhardt G Schurig
Stephen M Boyle
Nammalwar Srirangnanathan
Original Assignee
Veterinary Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veterinary Technologies Corp filed Critical Veterinary Technologies Corp
Publication of MX2012002829A publication Critical patent/MX2012002829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Este documento se refiere a los materiales y métodos para producir una respuesta inmunitaria para disminuir el riesgo de contagio por brucelosis. Por ejemplo, este documento proporciona vacunas para administrarlas a animales, así como los métodos para producir una respuesta inmunitaria contra bacterias que causan brucelosis empleando las vacunas que se proporcionan en la presente. Las vacunas que se proporcionan en la presente pueden ser eficaces para disminuir el riesgo de adquirir brucelosis a partir de múltiples especies de Brucella.
MX2012002829A 2009-10-21 2010-04-06 Producción de una respuesta inmune para disminuir el riesgo de contagio por brucelosis. MX2012002829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/589,299 US20100226942A1 (en) 2008-10-30 2009-10-21 Producing an immune response for reducing the risk of developing brucellosis
PCT/US2010/001040 WO2011049590A1 (en) 2009-10-21 2010-04-06 Producing an immune response for reducing the risk of developing brucellosis

Publications (1)

Publication Number Publication Date
MX2012002829A true MX2012002829A (es) 2012-12-17

Family

ID=42678459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002829A MX2012002829A (es) 2009-10-21 2010-04-06 Producción de una respuesta inmune para disminuir el riesgo de contagio por brucelosis.

Country Status (6)

Country Link
US (2) US20100226942A1 (es)
EP (1) EP2491142A4 (es)
CN (1) CN102597262A (es)
BR (1) BR112012008237A2 (es)
MX (1) MX2012002829A (es)
WO (1) WO2011049590A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372187B8 (es) * 2009-12-03 2013-04-29 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de identificación de animales vacunados frente a brucella.
WO2014036438A2 (en) * 2012-08-30 2014-03-06 Montana State University Live brucellosis vaccines comprising attenuated brucella mutants
WO2016005390A1 (en) * 2014-07-10 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Modified bacteria for improved vaccines against brucellosis
CN106854654B (zh) * 2017-02-16 2020-06-23 内蒙古医科大学 表达羊种布氏菌L7/L12基因的rBCG及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044431A1 (en) * 1998-06-19 2003-03-06 Gerhardt Schurig Over-expressing homologous antigen vaccine and a method of making the same
WO2004054508A2 (en) * 2002-12-12 2004-07-01 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis

Also Published As

Publication number Publication date
BR112012008237A2 (pt) 2020-08-18
CN102597262A (zh) 2012-07-18
WO2011049590A1 (en) 2011-04-28
EP2491142A4 (en) 2013-09-04
EP2491142A1 (en) 2012-08-29
US20100226942A1 (en) 2010-09-09
US20120202270A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
MX2011007930A (es) Conjugados de insulina cristalina.
MX2019002979A (es) Formulaciones de anticuerpos.
GB0917002D0 (en) Improved shigella blebs
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
IT1398553B1 (it) Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
MX353579B (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
MY170720A (en) Antibody formulations
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
SG10201900041VA (en) Meningococcus vaccines
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX361533B (es) Anticuerpos anti-cd22.
FI20116228A (fi) Menetelmä tuhkan, erityisesti lentotuhkan käsittelemiseksi
PH12014502855B1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
EP2571982A4 (en) ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
IN2014CN04071A (es)
GB2518813A (en) OMV vaccine against Burkholderia infections
MX2016007559A (es) Serie de formulas infantiles adaptadas a la edad con contenido de lactosa y contenido de proteinas optimos.
MX2016006551A (es) Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
MY173304A (en) Induction of immune tolerance using methotrexate
MX2014007558A (es) Composisiones para el cuidado oral.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
GB201017519D0 (en) Vaccines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal